Strategies for decreasing multidrug antibiotic resistance role of ototopical agents for treatment of middle ear infections

American Journal of Managed Care

Volumn 8, Issue 14 SUPPL., 2002, Pages

  Klein, Jerome O ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM ACETATE SOLUTION; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; CIPRO HC; COLISTIN; CORTANE B; CORTISPORIN; CORTISPORIN TC; COTRIMOXAZOLE; FLOXIN OTIC; GATIFLOXACIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFLUENZA VACCINE; LEVOFLOXACIN; MACROLIDE; METICILLIN; NAFCILLIN; OFLOXACIN; OTOCORT; OXACILLIN; PEDIOTIC; PENICILLIN G; PENICILLIN G DERIVATIVE; PENICILLIN V; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; UNINDEXED DRUG; VANCOMYCIN; VOSOL; VOSOL HS; ZOTO HC;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; CHILDHOOD DISEASE; CHRONIC OTITIS MEDIA; CLINICAL TRIAL; CLONE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG USE; ENTEROBACTERIACEAE; ENZYME INACTIVATION; ENZYME SYNTHESIS; EXTERNAL OTITIS; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INCIDENCE; MEDICAL PRACTICE; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NONHUMAN; OTITIS MEDIA; PATHOGENESIS; PENICILLIN RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; REVIEW; RISK FACTOR; STAPHYLOCOCCUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE; TYMPANOSTOMY TUBE;

ACUTE DISEASE; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; CHRONIC DISEASE; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; EDUCATION, MEDICAL, CONTINUING; HUMANS; MIDDLE EAR VENTILATION; OTITIS MEDIA; PATIENT EDUCATION; RISK FACTORS; UNITED STATES; VACCINES;

EID: 0036805390     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Barnett ED, Klein JO. Clinical implications of antibiotic resistance in bacterial infections of the upper respiratory tract. Advances in Otolaryngology-Head and Neck Surgery. 1997;11:89-111.
2. Klugman KP. Antibiotic selection of multiply resistant pneumococci. Clin Infect Dis. 2001;33:489-491.
3. Applebaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis. 2002;34:1613-1620.
4. Jacobs MR, Bajaksouzian S, Zilles A, et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study. Antimicrob Agents Chemother. 1999;43:1901-1908.
5. Thornsberry C, Ogilvie PT, Holley HP Jr, Sahm DF. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolates to 26 antimicrobial agents; a prospective US study. Antimicrob Agents Chemother. 1999;43:2612-2623.
6. Dowell SF, Marcy SM, Phillips WR, et al. Otitis media-principles of judicious use of antimicrobial agents. Pediatrics. 1998;101:165-171.
7. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2002;19:187-195.
8. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
9. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6 to 30 month old children in day care. Arch Pediatr Adolesc Med. 1995;149:113-117.
10. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med. 1998;338:1459-1461.
11. Dohar JE, Alper CM, Rose EA, et al. Treatment of chronic suppurative otitis media with topical ciprofloxacin. Ann Otol Rhinol Laryngol. 1998;107:865-871.
12. Force RW, Hart MC, Plummer SA, et al. Topical ciprofloxacin for otorrhea after tympanostomy tube placement. Arch Otolaryngol Head Neck Surg. 1995;121:880-884.
13. Bluestone CD. Efficacy of ofloxacin and other ototopical preparations for chronic suppurative otitis media in children. Pediatr Infect Dis J. 2001;20:111-115.
14. Agro AS, Garner ET, Wright JWIII, et al. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. Clin Ther. 1998;20:744-759.
15. Kozak LJ, Hall ME, Pokras R, Lawrence L. Ambulatory Surgery in the United States, 1994. Data from Vital and Health Statistics of the Centers for Disease Control. Atlanta, Ga. National Center for Health Statistics; 1997. 283:1-15.
16. Ah-Tye C, Paradise JL, Colton DK. Otorrhea in young children after tympanostomy-tube placement for persistent middle ear effusion: prevalence, incidence and duration. Pediatrics. 2001;107:1251-1258.
17. Goldblatt EL, Dohar J, Nozza R, et al. Topical ofloxacin versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes. Int J Pediatr Otorhinolaryngol. 1998;46:91-101.
18. Bormann L, Tang-Liu DD, Kann J, Nista J, Lin ET, Frank JR. Ofloxacin in human serum, urine, and tear film after topical application. Cornea. 1992;11:226-230.